NVIDIA CEO Unveils ‘First Big Bet’ on Digital Biology Revolution with UK-Based Cambridge-1
Introducing NVIDIA’s “first big bet” on the digital biology revolution, NVIDIA CEO Jensen Huang Wednesday unveiled Cambridge-1, a $100 million investment that promises to harness partnerships across the U.K. for breakthroughs with a “global impact.”
The U.K.’s most powerful supercomputer, Cambridge-1 will advance research at AstraZeneca, GSK, King’s College London, Oxford Nanopore, and Guy’s and St Thomas’ NHS Foundation Trust.
As part of Wednesday’s inauguration event, Cambridge-1’s founding partners outlined their plans to use Cambridge-1 to tackle new healthcare challenges during a panel discussion.
“We’re at the beginning of the digital biology revolution, and to do this work scientists need a powerful rocket for their journey,” Huang said. “Cambridge-1 brings together decades of our work in accelerated computing, AI and life sciences into a single computing center.”
Cambridge-1 is named for the birthplace of genomics, Huang explained during the virtual event. Cambridge is also the site of Arm’s headquarters, which NVIDIA agreed to acquire last year, and that Huang hopes to make NVIDIA’s “future home in the U.K.”
